CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 54 enrolled
Drug / intervention
Indacaterol 150 μg +2 moredrug
Likely dose
Indacaterol 150 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00999908
NCT00999908Phase 3Completed
CompareCT.gov

Multicenter, Randomized, Blinded, Placebo-controlled, Crossover, Single-dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients

Novartis Pharmaceuticals·interventional·Posted Oct 22, 2009·Updated Feb 17, 2016

In Brief

A Phase 3 clinical trial evaluating Indacaterol 150 μg, Tiotropium 18 μg, and 1 other intervention for Chronic Obstructive Pulmonary Disease. Completed, enrolled 54 participants across 11 sites.

Detailed Summary

This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease
CountriesItaly
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 22, 2009
Enrollment StartOct 1, 2009
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.7 years ago

Interventions

Indacaterol 150 μgdrug

Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

Tiotropium 18 μgdrug

Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.

Placebodrug

Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.